Competitor Landscape Skill

Competitor Landscape Skill

Comprehensive competitive intelligence for drug development decisions.

Quick Start

/​competitor EGFR inhibitors
/​competitor-landscape KRAS G12C drugs
Compare all EGFR TKIs in clinical development
Who's developing GLP-1R agonists for obesity?

What's Included

Output Structure

# EGFR Inhibitors - Competitive Landscape

## Executive Summary
The EGFR inhibitor market is mature but evolving. 9 drugs approved with
3rd-generation TKIs dominating. Pipeline focuses on resistance mechanisms
and CNS penetration. Key battleground: 4th-generation agents for C797S.

## Market Overview
| Metric | Value |
|--------|-------|
| Approved Drugs | 9 (5 TKIs, 4 antibodies) |
| In Development | 34 candidates (21 clinical) |
| Market Size | $12B globally (2023) |
| Key Companies | AstraZeneca, Roche, Boehringer |

## 1. Competitive Map by Company

### AstraZeneca (Leader)
| Drug | Type | Phase | Differentiation |
|------|------|-------|----------------|
| Osimertinib | 3rd-gen TKI | Approved | Standard of care |
| AZD9291 + savolitinib | Combo | III | MET amp resistance |

### Roche
| Drug | Type | Phase | Status |
|------|------|-------|--------|
| Erlotinib | 1st-gen TKI | Approved | Generic |
| Tiragolumab + atezo | TIGIT + EGFR | III | Combo |

[... more companies ...]

## 2. Approved Drugs Analysis

| Drug | Company | Launch | Type | Key Indication | Sales 2023 |
|------|---------|--------|------|----------------|------------|
| Osimertinib | AstraZeneca | 2015 | 3rd-gen TKI | NSCLC 1st line | $5.8B |
| Erlotinib | Astellas | 2004 | 1st-gen TKI | NSCLC 2nd line | $0.3B |
| Gefitinib | AstraZeneca | 2003 | 1st-gen TKI | NSCLC | $0.2B |
| Necitumumab | Eli Lilly | 2015 | Antibody | Squamous NSCLC | Discontinued |
| Amivantamab | J&J | 2021 | Bispecific | Exon20ins | $0.2B |

## 3. Pipeline by Development Phase

### Phase III
| Drug | Company | Differentiation | Readout |
|------|---------|----------------|---------|
| Lazertinib | Yuhan/​J&J | 3rd-gen, WT sparing | 2024 H2 |
| Nazartinib | Novartis | CNS active | 2024 Q3 |
| Patritumab deruxtecan | Daiichi Sankyo | ADC | 2025 |

### Phase II
| Drug | Company | Mechanism | Novelty |
|------|---------|-----------|---------|
| BLU-945 | Blueprint | 4th-gen (C797S) | First-in-class |
| BPI-9016M | Betta | 4th-gen | C797S focus |
| ... | ... | ... | ... |

## 4. Mechanism of Action Classification

| Class | Count | Status |
|-------|-------|--------|
| 1st-gen TKI | 3 approved | Generic |
| 2nd-gen TKI | 2 approved | Mature |
| 3rd-gen TKI | 3 approved | Dominant |
| 4th-gen TKI | 5 in clinic | Emerging |
| Antibodies | 4 approved | Niche |
| Bispecifics | 3 in clinic | Emerging |
| ADCs | 4 in clinic | Hot area |

## 5. Key Development Trends

### 2023-2024 Trends
1. **4th-generation TKIs**: Focus on C797S resistance mutation
2. **CNS penetration**: Critical for brain mets
3. **Combination therapies**: EGFR + MET, EGFR + chemotherapy
4. **ADC approach**: HER3-ADC, MET-ADC combinations
5. **Bispecifics**: Amivantamab leading

### White Space Opportunities
| Area | Rationale |
|------|-----------|
| 4th-gen TKI | C797S mutation unaddressed |
| Brain mets | High unmet need |
| Early detection | Neoadjuvant setting |
| Resistance combo | MET amp, HER3 upregulation |

## 6. Company Profiles

### AstraZeneca (Market Leader)
- **Portfolio**: Osimertinib (core), Tagrisso + chemoprev (adjuvant)
- **Strategy**: Extend osimertinib lifecycle (adjuvant, combo)
- **Strengths**: First-mover, brand recognition
- **Weaknesses**: Patent cliff approaching

### Emerging Players
- **Blueprint Medicines**: 4th-gen TKI leader (BLU-945)
- **J&J**: Combo strategy (lazertinib + EGFR/​c-MET bispecific)
- **Daiichi Sankyo**: ADC approach (patritumab deruxtecan)

## 7. Investment & Deals (Recent)

| Deal | Type | Value | Year |
|------|------|-------|------|
| J&J / Yuhan | Licensing | $1.2B | 2018 |
| Merck / Daiichi Sankyo | Combo partnership | $4.5B | 2023 |
| BMS / Turning Point | Acquisition | $4.1B | 2023 |

## 8. Go/​No-Go Considerations

### Green Light Signals
- C797S mutation space open
- CNS penetration unmet
- Combination approaches working

### Red Light Signals
- 3rd-gen crowded
- Generic erosion (1st/​2nd gen)
- High clinical trial costs

### Yellow Light Signals
- 4th-gen clinical risk (first-in-class)
- Combination regulatory complexity

Examples

Drug Class Analysis

/​competitor EGFR TKIs
/​competitor GLP-1R agonists
/​competitor PCSK9 inhibitors

Disease Area Analysis

/​competitor NSCLC therapies
Compare Alzheimer's drugs in development
/​competitor obesity medications --phase 2-3

Company Portfolio

What is AstraZeneca's oncology pipeline?
Compare Roche vs Novartis in hematology
/​competitor "Company Name" portfolio

Mechanism Focus

/​competitor KRAS G12C inhibitors
Compare all PROTAC degraders in clinic
/​competitor antibody-drug conjugates

Running Scripts

# Fetch competitive landscape data
python scripts/​fetch_competitor_data.py "EGFR inhibitors" --output data.json

# Include clinical trials
python scripts/​fetch_competitor_data.py "KRAS" --clinical-trials -o full.json

# Company-specific
python scripts/​fetch_competitor_data.py --company "AstraZeneca" --indication oncology

Requirements

pip install requests pandas lxml

Additional Resources

• ChEMBL API Reference
• Competitive Analysis Framework
• Company Data Sources

Best Practices

1. Be specific: Use drug class names (e.g., "3rd-gen EGFR TKI")
2. Define scope: Specify indication, phase, or company
3. Compare: Ask for competitive positioning
4. Look for white space: Ask about unaddressed areas

Common Pitfalls